Gene Therapy Program | University of Pennsylvania

gtp.med.upenn.edu

Dedicated to discovery + translational research and led by Dr James Wilson, the Gene Therapy Program at the University of Pennsylvania focuses on the development of next-generation gene transfer vectors and their application in the treatment of a variety of acquired and inherited diseases.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INDUSTRIAL IMPACT

XTALPI AND CK LIFE SCIENCES TO COLLABORATE IN AI-EMPOWERED TUMOUR VACCINE RESEARCH AND DEVELOPMENT, OPENING A NEW PARADIGM FOR SCIENTIFIC INNOVATION

XtalPi Inc. | November 25, 2022

news image

XtalPi announced today that they are embarking on a strategic collaboration with CK Life Sciences, a member of the CK Hutchison Group. XtalPi and CK Life Sciences will leverage their respective expertise to jointly develop a novel AI tumour vaccine R&D platform to improve the discovery and design capabilities of tumour vaccines and accelerate the development of more vaccine types. The goal of this collaboration is to realize precision treatment for patients worldwide. Accordin...

Read More

MEDICAL

DXTERITY DIAGNOSTICS ANNOUNCES THE LAUNCH OF IFN-1 TEST FOR LUPUS

DxTerity | June 13, 2022

news image

DxTerity Diagnostics today announced the commercial launch of their IFN-1 Test for patients with Systemic Lupus Erythematosus (SLE or lupus). The IFN-1 Test supports the advancement of precision medicine to improve the lives of patients living with lupus. DxTerity's test measures a key biomarker, Type-1 Interferon (IFN-1), an important indicator of SLE disease severity and prognosis. High IFN-1 levels have been shown to lead to higher likelihood of disease severity and an incr...

Read More

MEDICAL

PFIZER INVESTS $120 MILLION IN FOUR CLINICAL-STAGE BIOTECH COMPANIES THROUGH THE PFIZER BREAKTHROUGH GROWTH INITIATIVE

Pfizer | January 15, 2021

news image

Pfizer Inc. declared that, during the second 50% of 2020, it put a sum of $120 million of every four clinical-stage biotech organizations as a feature of the Pfizer Breakthrough Growth Initiative (PBGI). Through PBGI, Pfizer is putting up to $500 million in biotechnology organizations, giving subsidizing and admittance to Pfizer's logical skill to help guarantee the coherence of promising clinical improvement projects of likely future vital interest to Pfizer. Pfizer's ini...

Read More

MEDICINAL GENOMICS ANNOUNCES NEW PATHOSEEK® ASPERGILLUS MULTIPLEX ASSAY TO STREAMLINE CANNABIS TESTING

BioSpace | February 27, 2020

news image

Medicinal Genomics (MGC), a pioneer in harnessing cannabis genomics to improve the agricultural productivity, safety, and transparency of cannabis, today announced its new PathoSEEK® 5-Color Aspergillus Multiplex Assay that independently identifies four species of pathogenic Aspergillus— A. flavus, A. fumigatus, A. niger, and A. terreus — on cannabis samples using just one qPCR reaction. This new Aspergillus assay is the first and only qPCR multiplex that can satisfy the Californ...

Read More
news image

INDUSTRIAL IMPACT

XTALPI AND CK LIFE SCIENCES TO COLLABORATE IN AI-EMPOWERED TUMOUR VACCINE RESEARCH AND DEVELOPMENT, OPENING A NEW PARADIGM FOR SCIENTIFIC INNOVATION

XtalPi Inc. | November 25, 2022

XtalPi announced today that they are embarking on a strategic collaboration with CK Life Sciences, a member of the CK Hutchison Group. XtalPi and CK Life Sciences will leverage their respective expertise to jointly develop a novel AI tumour vaccine R&D platform to improve the discovery and design capabilities of tumour vaccines and accelerate the development of more vaccine types. The goal of this collaboration is to realize precision treatment for patients worldwide. Accordin...

Read More
news image

MEDICAL

DXTERITY DIAGNOSTICS ANNOUNCES THE LAUNCH OF IFN-1 TEST FOR LUPUS

DxTerity | June 13, 2022

DxTerity Diagnostics today announced the commercial launch of their IFN-1 Test for patients with Systemic Lupus Erythematosus (SLE or lupus). The IFN-1 Test supports the advancement of precision medicine to improve the lives of patients living with lupus. DxTerity's test measures a key biomarker, Type-1 Interferon (IFN-1), an important indicator of SLE disease severity and prognosis. High IFN-1 levels have been shown to lead to higher likelihood of disease severity and an incr...

Read More
news image

MEDICAL

PFIZER INVESTS $120 MILLION IN FOUR CLINICAL-STAGE BIOTECH COMPANIES THROUGH THE PFIZER BREAKTHROUGH GROWTH INITIATIVE

Pfizer | January 15, 2021

Pfizer Inc. declared that, during the second 50% of 2020, it put a sum of $120 million of every four clinical-stage biotech organizations as a feature of the Pfizer Breakthrough Growth Initiative (PBGI). Through PBGI, Pfizer is putting up to $500 million in biotechnology organizations, giving subsidizing and admittance to Pfizer's logical skill to help guarantee the coherence of promising clinical improvement projects of likely future vital interest to Pfizer. Pfizer's ini...

Read More
news image

MEDICINAL GENOMICS ANNOUNCES NEW PATHOSEEK® ASPERGILLUS MULTIPLEX ASSAY TO STREAMLINE CANNABIS TESTING

BioSpace | February 27, 2020

Medicinal Genomics (MGC), a pioneer in harnessing cannabis genomics to improve the agricultural productivity, safety, and transparency of cannabis, today announced its new PathoSEEK® 5-Color Aspergillus Multiplex Assay that independently identifies four species of pathogenic Aspergillus— A. flavus, A. fumigatus, A. niger, and A. terreus — on cannabis samples using just one qPCR reaction. This new Aspergillus assay is the first and only qPCR multiplex that can satisfy the Californ...

Read More